Intas Entered into an Exclusive License Agreement with Syna to Commercialize Biosimilar LB-0702
- The companies collaborated to commercialize the biosimilar drug LB-0702 to treat pathologies in the field of haematology. The clinical trials for LB-0702 are expected to be initiated in 2023 with the support of its partner Leanbio and Reig Jofre
- Intas to get an exclusive license right to commercialize LB-0702 globally while Syna will be responsible to develop and manufacture LB-0702 and supply the product to Intas and its affiliates
- Leanbio's technology platforms will be used to develop and manufacture the biosimilar, along with Reig Jofre's technology production expertise at its new manufacturing plant in Barcelona which specializes in sterile injectables and freeze-dried biopharmaceuticals
Ref: PRNewswire | Image: Intas
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at firstname.lastname@example.org.